Breaking News, Collaborations & Alliances

Sunesis, Royalty Pharma in Vosaroxin Pact

Royalty invests $25 million for development of AML drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Royalty Pharma entered an agreement to acquire royalties on future worldwide sales of vosaroxin, Sunesis’ lead product candidate. Royalty Pharma will pay Sunesis $25 million for certain development milestones. Sunesis is evaluating vosaroxin in a Phase III VALOR trial in patients with first relapsed or refractory acute myeloid leukemia (AML). Royalty Pharma will invest $25 million immediately following interim analysis of the trial in exchange for 3.6% on future sales. If the trial sample size ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters